Services
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Single & Multiple-Dose In Vivo Pharmacokinetic (PK) Profiling Service
Are you currently facing the challenge of ensuring the translational relevance of your preclinical data for complex biologics? Do you need a reliable pathway to predict human PK profiles and optimize first-in-human dosing? Our NHP Single and Multiple-Dose PK Profiling service helps you accelerate drug development and de-risk your lead candidates through advanced in vivo models and state-of-the-art bioanalytical techniques.
Introduction to NHP PK Services
In vivo pharmacokinetic (PK) studies in NHP are fundamental to contemporary preclinical drug development. These studies offer an in-depth evaluation of a drug's or compound's behavior in a living organism, emphasizing the ADME processes of the substance under investigation. This approach measures drug concentrations across various biological matrices over time, which is crucial for comprehending the fundamental dynamics of a drug and foreseeing its clinical trajectory.
What Our Service Is
Our NHP PK profiling service provides a crucial bridge between in vitro data and human clinical trials. We offer both single-dose studies, which are designed to evaluate a drug's initial PK profile and key parameters like half-life and clearance, and multiple-dose studies, which assess drug accumulation and steady-state concentrations. These studies are indispensable for the design of safe and effective clinical dosing regimens.
- Monoclonal Antibodies (mAbs): NHPs are often the only non-clinical species with a relevant target expression and immunological similarity to humans for testing therapeutic antibodies.
- Gene Therapies: For complex molecules and modalities like gene therapies, NHPs provide the only relevant in vivo model to assess biodistribution, long-term expression, and potential immunogenicity.
- Novel Biologics: As the industry diversifies into new modalities like antibody-drug conjugates (ADCs) and bispecific T-cell engagers, NHPs remain the gold standard for providing predictive PK data.
Why Choose Us?
Drug development is a high-stakes endeavor where every decision counts. The wrong preclinical model can lead to costly failures and delays. Our value proposition is simple yet profound: we provide a reliable and predictive platform that mitigates risk and accelerates your path to the clinic. By utilizing NHP models, we address the critical pain point of species specificity, especially for biologics that may not cross-react in rodents. Our data-driven approach and flexible study designs provide you with the most translationally relevant insights, saving you time and resources.
Key Benefits of Our Service
Our deep expertise and advanced capabilities are designed to provide a seamless and highly effective service. We understand the need for speed and accuracy in a competitive landscape, and our services are tailored to meet those demands.
- Swift Response and High Throughput: Our efficient processes and dedicated team ensure rapid turnaround times from study initiation to final report generation. We provide standard non-compartmental analysis (NCA) parameters within a competitive timeframe, enabling you to make crucial go/no-go decisions faster.
- Unmatched NHP Resources: With access to robust and ethically managed NHP populations, including Cynomolgus, Rhesus, Marmoset, and African Green Monkey, we can initiate studies quickly and scale to meet your project's needs without supply chain delays.
- Customization and Flexibility: We believe in a collaborative approach. Our experienced study directors work with you to design a customized study protocol that precisely matches your project's scientific goals, whether it's a standard PK screen or a more complex PK/PD investigation.
- In-Depth Reporting and Analysis: Our final reports are not just a collection of numbers; they are a clear and comprehensive analysis of your drug's PK profile, complete with PK modeling and simulation. This allows for informed decision-making and better dose projections for first-in-human studies.
How Creative Biolabs' Service Can Assist Your Project?
Our services are built to provide actionable solutions and clear, reliable deliverables. We demystify the process and provide a transparent, step-by-step approach to help you achieve your project milestones.
01
Required Starting Materials
02
Consultation and Study Design
03
In-life Phase
04
Bioanalysis
05
PK Modeling and Data Analysis
06
Final Deliverables
Key Deliverables
Comprehensive study report detailing methods, results, and interpretation.
- Raw data files from bioanalytical assays.
- Summary of PK parameters.
- PK modeling and simulation reports.
- Graphs and figures illustrating drug concentration-time profiles.
Capabilities & Partnerships
Service-Specific Data
- Annual Sample Size: 50000+
- Typical Turnaround Time: 8-12 weeks
- Method Validation Pass Rate: 95%+
Our Valued Partners
Frequently Asked Questions
Q: How do you ensure the translational relevance of NHP data to humans?
A: Our team understands the critical physiological and genetic similarities between NHPs and humans, particularly for biologics. We apply the latest insights in allometric scaling and PBPK modeling, coupled with published data on species-specific differences, to provide the most predictive PK profiles possible for your first-in-human studies.
Q: Are there alternative models I can use to reduce NHP usage?
A: We are fully committed to the 3Rs of animal research (Reduce, Refine, Replace). While alternative in vitro and in silico models are valuable tools, NHPs remain the most relevant species for many complex biologics. We work with our clients to design the most efficient studies possible to minimize the number of animals required without compromising scientific rigor.
Q: How do you handle potential immunogenicity in NHP studies?
A: Immunogenicity is a common consideration in NHP studies for biologics. Our protocols are designed to monitor and detect anti-drug antibodies (ADA), and we can integrate immunogenicity testing into your study. Understanding the impact of ADA on your drug's PK profile is a critical part of the data we deliver.
Q: How does your PK profiling service integrate with other preclinical studies, such as toxicology?
A: Our PK profiling service is a crucial part of an integrated preclinical package. We can seamlessly coordinate with your toxicology and safety assessment studies, often using the same animals or samples, to provide a complete picture of your drug's behavior, safety, and efficacy. This integrated approach saves time and resources while providing a holistic dataset.
Contact Us
At Creative Biolabs, we specialize in providing the high-quality, translational PK data that propels your drug development program forward. Our NHP Single and Multiple-Dose PK Profiling service combines scientific rigor, advanced bioanalytical capabilities, and a commitment to client success. Contact us today to learn how our preclinical services can accelerate your journey to the clinic.